Our results and those of others (4, 46) are not consistent with those obtained in a genetically engineered mouse model of mutant KRAS-driven NSCLC, in which ASNS has been shown to be rate limiting for tumorigenesis (26). This evidence concerns the gene KRAS and non-small cell lung carcinoma.